CryoLife announced Wednesday that its subsidiary AuraZyme Pharmaceuticals had received a $100,000 grant to study the feasibility of using its AZ-Plasmin Drug Technology in treating blood clots.
The grant is coming from the National Institutes of Health.
The AuraZyme clot treatment is intended to produce fewer side effects than typical clot dissolving drugs, the company said in a statement.
CryoLife: www.cryolife.com
